Cytokine conjugates for the treatment of autoimmune diseases
AssigneeSynthorx, Inc.
InventorsCarolina E. Caffaro, Marcos Milla, Jerod Ptacin
Life of this patent
Estimating the term…
Abstract
Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
Claims23
A method of expanding CD4+ regulatory T (Treg) cells in a subject in need thereof, comprising administering to a subject having an autoimmune disease or disorder a therapeutically effective amount of a modified interleukin 2 (IL-2) polypeptide comprising an IL-2 polypeptide comprising at least one unnatural amino acid covalently attached to a conjugating moiety,
- wherein the position of the at least one unnatural amino acid is K9, H16, L19, V91, E100, or T123, wherein the residue positions correspond to positions 9, 16, 19, 91, 100, and 123 as set forth in SEQ ID NO:
- 1;
- and
- wherein the IL-2 polypeptide comprises at least 90% sequence identity to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.